Relypsa, Inc.
Biotechnology
Redwood City, California
Public Corporation
Our Company
In 2014, we completed the eighth clinical study of our lead product candidate. We submitted our New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking an indication for the treatment of hyperkalemia. In January, FDA indicated they anticipated their review to be completed in October 2015.Skills We're Looking For
Adobe Acrobat
Devloping Applications
Collaboration
Microsoft Excel
Microsoft PowerPoint
Microsoft Word
Reports
Science
Scientific Reasoning
International Law
